Kineta Receives $600,000 Phase 1 Small Business Innovation Research (SBIR) Grant

Kineta, Inc., a Seattle, WA-based, biotechnology company specializing in clinical advancement of drugs that modulate and enhance the human immune system, received a $600,000 Phase 1 Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).
Awarded under the NIAID’s expanded Phase 1 program, the two-year grant will help finance IND-enabling studies of ShK-186, Kineta’s therapeutic for type 1 diabetes mellitus, multiple sclerosis and other autoimmune diseases.
The company intends to begin human clinical trials on the investigational drug in the second half of 2010.
The award includes a subcontract to George Chandy, M.D., Ph.D. of the University of California at Irvine for mechanistic studies.

Join the discussion